

# GBA3 Rabbit pAb

GBA3 Rabbit pAb  
Catalog # AP55124

## Product Information

---

<b>Application</b>	IHC-P, IHC-F, IF
<b>Primary Accession</b>	<a href="#">Q9H227</a>
<b>Reactivity</b>	Mouse, Rat
<b>Predicted</b>	Human, Pig, Horse, Sheep
<b>Host</b>	Rabbit
<b>Clonality</b>	Polyclonal
<b>Calculated MW</b>	53696
<b>Physical State</b>	Liquid
<b>Immunogen</b>	KLH conjugated synthetic peptide derived from human GBA3/CBG
<b>Epitope Specificity</b>	151-250/469
<b>Isotype</b>	IgG
<b>Purity</b>	affinity purified by Protein A
<b>Buffer</b>	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
<b>SUBCELLULAR LOCATION</b>	Cytoplasm; cytosol.
<b>SIMILARITY</b>	Belongs to the glycosyl hydrolase 1 family. Klotho subfamily.
<b>Post-translational modifications</b>	The N-terminus is blocked.
<b>Important Note</b>	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
<b>Background Descriptions</b>	CBG is a monomeric enzyme involved in the absorption and metabolism of flavonoid glucosides. CBG is found predominately in the liver, but is also located in tissues such as spleen, small intestine and kidney. Through its catalytic activity, CBG is able to hydrolyze a variety of glycosides including phytoestrogens, cyanogens, and flavonols. Although its catalytic activity extends to many dietary flavonoids, CBG has increased specificity for hydrophobic aglycones such as beta-D-glucoside and beta-D-galactoside. Hydrolysis is inhibited by sodium taurocholate and glucosyl-sphingosine, both of which regulate CBG enzymatic activity. Deficiencies in CBG have been implicated in Gaucher's disease, a lysosomal storage disease that causes a build up of fatty material in the spleen, liver, lung and kidneys.

## Additional Information

---

<b>Gene ID</b>	57733
<b>Other Names</b>	Cytosolic beta-glucosidase, 3.2.1.21, Cytosolic beta-glucosidase-like protein 1, Cytosolic galactosylceramidase, 3.2.1.46, Cytosolic glucosylceramidase, 3.2.1.45, Cytosolic glycosylceramidase, Cytosolic GCase, Glucosidase beta acid 3 {ECO:0000312 HGNC:HGNC:19069}, Glucosylceramidase beta 3 {ECO:0000312 HGNC:HGNC:19069}, Klotho-related protein, KLrP, GBA3 ( <a href="#">HGNC:19069</a> ), CBG, CBGL1

<b>Target/Specificity</b>	Present in small intestine (at protein level). Expressed in liver, small intestine, colon, spleen and kidney. Down-regulated in renal cell carcinomas and hepatocellular carcinomas.
<b>Dilution</b>	IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
<b>Storage</b>	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

## Protein Information

---

<b>Name</b>	GBA3 ( <a href="#">HGNC:19069</a> )
<b>Synonyms</b>	CBG, CBGL1
<b>Function</b>	Neutral cytosolic beta-glycosidase with a broad substrate specificity that could play a role in the catabolism of glycosylceramides (PubMed: <a href="#">11389701</a> , PubMed: <a href="#">11784319</a> , PubMed: <a href="#">17595169</a> , PubMed: <a href="#">20728381</a> , PubMed: <a href="#">26724485</a> , PubMed: <a href="#">33361282</a> ). Has a significant glucosylceramidase activity in vitro (PubMed: <a href="#">17595169</a> , PubMed: <a href="#">26724485</a> ). However, that activity is relatively low and its significance in vivo is not clear (PubMed: <a href="#">17595169</a> , PubMed: <a href="#">20728381</a> , PubMed: <a href="#">26724485</a> ). Hydrolyzes galactosylceramides/GalCers, glucosylsphingosines/GlcSphs and galactosylsphingosines/GalSphs (PubMed: <a href="#">17595169</a> ). However, the in vivo relevance of these activities is unclear (PubMed: <a href="#">17595169</a> ). It can also hydrolyze a broad variety of dietary glycosides including phytoestrogens, flavonols, flavones, flavanones and cyanogens in vitro and could therefore play a role in the metabolism of xenobiotics (PubMed: <a href="#">11784319</a> ). Possesses transxylosylase activity in vitro using xylosylated ceramides/XylCers (such as beta-D-xylosyl-(11')-N-acylsphing-4-enine) as xylosyl donors and cholesterol as acceptor (PubMed: <a href="#">33361282</a> ). Could also play a role in the catabolism of cytosolic sialyl free N-glycans (PubMed: <a href="#">26193330</a> ).
<b>Cellular Location</b>	Cytoplasm, cytosol
<b>Tissue Location</b>	Present in small intestine (at protein level). Expressed in liver, small intestine, colon, spleen and kidney. Down- regulated in renal cell carcinomas and hepatocellular carcinomas

## Background


---

CBG is a monomeric enzyme involved in the absorption and metabolism of flavonoid glucosides. CBG is found predominately in the liver, but is also located in tissues such as spleen, small intestine and kidney. Through its catalytic activity, CBG is able to hydrolyze a variety of glycosides including phytoestrogens, cyanogens, and flavonols. Although its catalytic activity extends to many dietary flavonoids, CBG has increased specificity for hydrophobic aglycones such as beta-D-glucoside and beta-D-galactoside. Hydrolysis is inhibited by sodium taurocholate and glucosyl-sphingosine, both of which regulate CBG enzymatic activity. Deficiencies in CBG have been implicated in Gaucher's disease, a lysosomal storage disease that causes a build up of fatty material in the spleen, liver, lung and kidneys.

## Images

---

Paraformaldehyde-fixed, paraffin embedded (rat kidney);  
Antigen retrieval by boiling in sodium citrate buffer



(pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (GBA3) Polyclonal Antibody, Unconjugated (AP55124) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.